Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Lead: Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
-
Narrado por:
-
De:
Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine
JAMA Network
This industry-sponsored, multicenter, open-label randomized clinical trial with 729 participants, assessed if rapid induction (RI) for initiating extended-release buprenorphine is as safe and effective as standard induction (SI) in individuals who inject opioids or use fentanyl. RI was well tolerated and had higher retention than SI at extended-release buprenorphine injection 2 overall and in fentanyl positive participants. Administering the second extended-release buprenorphine injection 1 week after the first was well tolerated in both the RI arm and SI arm. These findings suggest support RI for extended-release buprenorphine induction in high-risk patients and demonstrate the feasibility of administering the first 2 doses at least 1 week apart.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM